BOLD

Boundless Bio
BOLD

$3.71

0.8%

Market Cap: 82.6M

About: Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Employees: 72

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 3 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

20,778,197,900% more capital invested

Capital invested by funds: $0 [Q4 2023] → $208M (+$208M) [Q1 2024]

4,200% more funds holding

Funds holding: 0 [Q4 2023] → 42 (+42) [Q1 2024]

4,200% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 0

100% more funds holding in top 10

Funds holding in top 10: 0 [Q4 2023] → 1 (+1) [Q1 2024]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$20

439%

upside

Avg. target

$23

520%

upside

High target

$25

574%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

Leerink Partners Michael Cherny	574%upside $25	Outperform Initiated	22 Apr 2024
Guggenheim Yige Guo	547%upside $24	Buy Initiated	22 Apr 2024
Piper Sandler Joseph Catanzaro	439%upside $20	Overweight Initiated	22 Apr 2024

See Analyst Rankings

Financial journalist opinion

Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, and Jami Rubin, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. The fireside chat session is schedul.

Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results for the first quarter of 2024 and highlighted recent progress. “It has been an exciting quarter at Boundless Bio. The Phase 1/2 POTENTIATE trial of BBI-355, our potentially best-in-class, oral, selective CHK1 inhibitor.

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights

Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Boundless Bio Chief Financial Officer, Jami Rubin, will present at the Citizens JMP Life Sciences Conference 2024. The podium presentation is scheduled for Monday, May 13, in New York, NY, at 1:00 p.m. ET. A live and archived webca.

Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that the first patient has been dosed with BBI-825 in a first-in-human, Phase 1/2 clinical trial for patients with locally advanced or metastatic cancer with resistance gene amplifications (NCT06299761). ecDNA are a key driver of high c.

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, presents preclinical and clinical pharmacodynamic data on its lead ecDNA-directed therapy (ecDTx), BBI-355, and research on ecDNA-mediated acquired resistance to chemotherapy at the American Association for Cancer Research (AACR) Annual Meeting 2024. B.

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

24/7 Wall Street

Insiders Scoop Up Shares of These 5 Stocks for the Second Quarter

Although the number and size of insider purchases have been somewhat lower as the second quarter begins, the following beneficial owners and other insiders were still showing their love for these five stocks.

Insiders Scoop Up Shares of These 5 Stocks for the Second Quarter

U.S. IPO Weekly Recap: Biotech Leads Short 3 IPO Week

U.S. IPO Weekly Recap: Biotech Leads Short 3 IPO Week

U.S. IPO Weekly Recap: Biotech Leads Short 3 IPO Week

Boundless Bio Announces Pricing of Initial Public Offering

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio, Inc. (Nasdaq: BOLD), a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at an initial public offering price of $16.00 per share. All of the shares are being offered by Boundless Bio. The gross proceeds from the offering.

Boundless Bio Announces Pricing of Initial Public Offering

U.S. IPO Weekly Recap: Tech IPOs Pop As End Of March Approaches

U.S. IPO Weekly Recap: Tech IPOs Pop As End Of March Approaches

U.S. IPO Weekly Recap: Tech IPOs Pop As End Of March Approaches

Boundless Bio Starts $100 Million U.S. IPO Plan

Boundless Bio, Inc. has filed for a $100 million IPO to develop DNA treatments for various cancers. The firm's lead candidate, BBI-355, is in Phase 1 trials for the treatment of oncogene amplified cancers. The global market for solid tumor cancer treatments is forecasted to reach $532 billion by 2032, providing a large addressable market for Boundless Bio's technologies.

Boundless Bio Starts $100 Million U.S. IPO Plan

See News Rankings